2005-2006 Grant Cycle : Research Grants Awarded
Basic, Clinical and Translation
Estrogen Receptor -Tumor Suppressor p53 Interaction: A Basis for Novel Therapeutic Strategies against Breast Cancer
Gokul Das, PhD
Roswell Park Alliance Foundation
Tumor Cell Biology II
$250,000
Enhancing Antitumor Cytotoxic T Lymphocyte Function Using HER-2/neu-Specific Monoclonal Antibodies
Richard Reilly, PhD
Johns Hopkins University
Tumor Cell Biology III
$250,000
DNA Double-Strand Break (DSB) Repair In Breast Cancer Cells And shRNA Approach To Inhibition Of DSB Repair As A Way To Fight Therapy Resistance
Vera Gorbunova, PhD
University of Rochester
Treatment
$250,000
The Roles of p63 and p73 in the Pathogenesis of Mammary Adenocarcinoma
Elsa Flores, PhD
U.T.M.D. Anderson Cancer Center
Tumor Cell Biology V
$250,000
Detection and Analysis of Telomere Dysfunction in Breast Tumor Tissue
David Gilley, PhD
Indiana University
Tumor Cell Biology V
$250,000
Development of a DNA breast cancer vaccine
Vasso Apostolopoulos, PhD
Burnet Institute Incorporating The Austin Research Institute
Tumor Cell Biology III
$249,750
Breast MRI Screening in Women Treated with Mediastinal Irradiation for Hodgkin’s Disease
Andrea Ng, MD, MPH
Dana Farber Cancer Institute
Detection, Diagnosis and Prognosis
$249,900
The Effect of Melatonin's Efficacy at Reducing Primary and Metastatic Breast Cancer Risk
Paula Witt-Enderby, PhD
Duquesne University
Psycho-Social and Complementary Treatment
$250,000
Bi-specific Endothelin Receptor Antagonists for Breast Cancer Therapy
Masaki Imai, PhD
Medical University of South Carolina
Tumor Cell Biology I
$248,278
Adoptive Immunotherapy for HER2 Positive Breast Cancer with Genetically Modified T Cells
Stephen Gottschalk, MD
Baylor College of Medicine
Tumor Cell Biology III
$250,000
Mechanisms Underlying the Dual Action of Cellular Retinoic Acid Binding Protein II in Breast Tumor Suppression
Noa Noy, PhD
Cornell University
Tumor Cell Biology II
$249,722
Nischarin, a Novel Protein: a Strong Potential Tumor Suppressor and a Prognostic Marker of Breast Cancer
Suresh Alahari, PhD
Louisiana State University Health Sciences Center
Tumor Cell Biology V
$250,000
Radiation Targeting of Antivascular Drugs to Tumors
Mohammad Kiani, PhD
Temple University of the Commonwealth System of Higher Education
Tumor Cell Biology I
$250,000
Three-dimensional Computerized Detection and Diagnosis of Breast Cancer with Tomosynthesis
Xuejun Sun, PhD
H. Lee Moffitt Cancer Center and Research Institute
Detection, Diagnosis and Prognosis
$250,000
Chromosome Instability (CIN) In Breast Cancer Cells
Katsumi Kitagawa, PhD
St. Jude Children's Research Hospital
Tumor Cell Biology V
$250,000
The Role of Twist in Mammary Tumor Metastasis
Douglas Spicer, PhD
Maine Medical Center
Tumor Cell Biology I
$249,756
Early detection of high-risk patients with breast DCIS
S. Ashraf Imam, MS, PhD
Huntington Medical Research Institutes
Detection, Diagnosis and Prognosis
$250,000
Paced breathing for hot flashes in breast cancer survivors: a randomized Phase II study
Amit Sood, MD
Mayo Clinic Rochester d/b/a Mayo Clinic College of Medicine
Psycho-Social and Complementary Treatment
$250,000
The tumor stroma as a regulator of resistance to endocrine therapy.
Marina Simian, PhD
Instituto de Oncologia Angel H. Roffo
Tumor Cell Biology II
$249,999
BP1 Expression, Apoptosis, and Breast Cancer Aggressiveness in African American Women
Patricia Berg, PhD
The George Washington University
Tumor Cell Biology V
$250,000
Development of biological models to differentiate aggressive from indolent DCIS
Rachel Ellsworth, PhD
Windber Research Institute
Detection, Diagnosis and Prognosis
$249,998
Molecular Targeting Of DNA Repair: Determining The Functional Status Of The FA/BRCA Pathway In Non-Familial Breast Cancers
Lisa Kachnic, MD
Massachusetts General Hospital
Tumor Cell Biology V
$249,974
Synergy Between ErbB2 And The Breast Tumor Kinase Brk
W. Todd Miller, PhD
The Research Foundation
Tumor Cell Biology V
$249,906
Prevention of Early Pre-malignant Breast Lesions by an Aurora Kinase Inhibitor during Estrogen-induced ACI Rat Breast Oncogenesis
Jonathan Li, PhD
University of Kansas Medical Center
Treatment
$248,413
The Use of Zoledronate to Impact Organ Metastasis in Breast Cancer Patients
Barbara Fingleton, PhD
Vanderbilt University Medical Center
Tumor Cell Biology IV
$250,000
Molecular Mechanisms Responsible for the Neighbor Effect, the Mesenchymal Transition Induced in TGF-beta non-responsive Breast Cancer Cells by Adjacent Epithelial Cells
Michael Hoffmann, PhD
Board of Regents of the University of Wisconsin System
Tumor Cell Biology II
$248,620
Targeting STAT1 in the Treatment of Breast Cancer
David Frank, MD, PhD
Dana-Farber Cancer Institute
Treatment
$250,000
Genomic study of familial DCIS and invasive breast cancer to discover susceptibility genes
Wendy Rubinstein, MD, PhD
Evanston Northwestern Healthcare Research Institute
RISK and Prevention, Epidemiology
$250,000
Breast Cancer and the Plasminogen Activator Inhibitor-1 Cycle
Frank Church, PhD
University of North Carolina at Chapel Hill
RISK and Prevention, Epidemiology
$250,000
Individualized Risk Information System (IRIS) for BRCA Carriers
Jeffrey N. Weitzel, MD
Beckman Research Institute of the City of Hope
RISK and Prevention, Epidemiology
$250,000
Caffeic Acid Phenethyl Ester (CAPE, Product of Propolis) as Potential Preventive and/or Therapeutic Agent for Breast Cancer
Krystyna Frenkel, PhD
New York University School of Medicine
RISK and Prevention, Epidemiology
$249,764
Phenotypic Differences in Sub-types of DCIS: Aggressiveness and Race
William Grizzle, MD, PhD
The Board of Trustees of the Universtiy of Alabama for the University of Alabama at Birmingham
Detection, Diagnosis and Prognosis
$250,000
ATF-3: A Potential Target Gene for Breast Cancer Cell Growth and Metastasis
Nagarajan Selvamurugan, PhD
University of Medicine & Dentistry of New Jersey
Tumor Cell Biology II
$250,000
Penetratin-Based Vaccines for the Treatment of Breast Cancer
Geoffrey Pietersz, PhD
Burnet Institute at Austin, Kronheimer Building
Tumor Cell Biology III
$242,040
Targeted Gene Therapy for Breast Cancer Growth and Metastasis
Selvarangan Ponnazhagan, PhD
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
Treatment
$250,000
A Novel Herbal Medicine for Treatment of Breast Cancer
Damodaran Chendil, PhD
Univeristy of Kentucky Research Foundation
Psycho-Social and Complementary Treatment
$250,000
The Tumor Suppressing Effect of Pregnancy: Can the Mammary Stroma do the Job?
Maricel Maffini, PhD
Tufts University
Tumor Cell Biology IV
$250,000
Molecular Network Profiling of DCIS for Patient Stratification and Individualized Therapy
Kirsten Edmiston, MD
Inova Fairfax Hospital Cancer Center
Detection, Diagnosis and Prognosis
$250,000
Modeling Breast Cancer Initiation Through Genetic Manipulation of Mammary Stem Cells
James DiRenzo, PhD
Trustees of Dartmouth College
Tumor Cell Biology V
$250,000
Telomere Dysfunction and Breast Cancer Risk
Yun-Ling Zheng, MD, PhD, MPH
Georgetown University
RISK and Prevention, Epidemiology
$249,923
Sonography Compared with MRI in Pre-operative Evaluation of Patients with Breast Cancer to Determine Extent of Breast Disease
Linda Hovanessian-Larsen, MD
University of Southern California
Detection, Diagnosis and Prognosis
$245,117
Role Of CD1D1 In Breast Cancer Bone Metastasis
Ming Zhang, PhD
Baylor College of Medicine
Tumor Cell Biology IV
$250,000
Endoplasmic Reticulum Stress Induced Apoptosis of Capillary Endothelia: A New Target for Treating Breast Cancer
Dipak Banerjee, PhD
University of Puerto Rico - Medical Sciences Campus
Tumor Cell Biology I
$250,000
Combination immunotherapy of established breast cancer
Mark Smyth, PhD
Universty of Melbourne
Tumor Cell Biology III
$249,960
Estrogen Receptor Beta in Relation to Breast Cancer Proliferation
Guojun Cheng, MD, PhD
Dept. of Biosciences and Nutrition, Karolinska Institutet
Tumor Cell Biology II
$249,300
Prevention of chromosomal instability in breast cancer by indigo-derived CDK inhibitors
Stefan Duensing, MD
University of Pittsburgh
RISK and Prevention, Epidemiology
$249,814
Mechanisms of breast cancer-preventive effects of organosulfur compounds
Yong Lee, PhD
University of Pittsburgh
RISK and Prevention, Epidemiology
$250,000
Investigation of the Diagnostic Value of Diffusion Tensor MRI of the Breast
Savannah Partridge, PhD
University of Washington
Detection, Diagnosis and Prognosis
$243,619
Signaling Cross-Talk Converging On Survivin During Anti-Tumor Drug Action: A Potential New Concept For Breast Cancer Treatment
Fengzhi Li, PhD
Roswell Park Alliance Foundation
Treatment
$250,000
Breast Magnetic Resonance Assessment of Tumor Viability After Radiofrequency Ablation
Todd Tuttle, MD
The Regents of the University of Minnesota
Detection, Diagnosis and Prognosis
$250,000
Novel Array-Based Identification of Genes Causing Chemotherapy Resistance by Breast Cancer
Dan Mercola, MD, PhD
The Regents of the University of California
Tumor Cell Biology IV
$250,000
Polyamine Analogues As Novel Anti-Estrogen Receptor Alpha Agents
Nancy Davidson, MD
Johns Hopkins University, School of Medicine
Tumor Cell Biology II
$250,000
Lipid-induced breast cancer metastasis
Erhard Bieberich, PhD
Medical College of Georgia
Tumor Cell Biology I
$250,000
Synthesis Of Signal Transduction Inhibitor-Steroidal Antiestrogen Hybrids Using "Click Chemistry" And Their Evaluation As Breast Cancer Therapeutic Agents
Robert Hanson, PhD
Northeaster University
Treatment
$236,250
Targeting Breast Cancer at the Level of Translation Control
Matthias Gromeier, MD
Duke University
Tumor Cell Biology IV
$240,000
Sesquiterpene Lactones: Aspirins for Breast Cancer
Michael Van Dyke, PhD
The University of Texas M.D. Anderson Cancer Center
Tumor Cell Biology V
$249,000
Developing Anti-Breast Cancer Therapies Based on G3BP
Derek Kennedy, PhD
Griffith University
Tumor Cell Biology III
$247,478
Estrogen and Progestin Regulation of Thrombospondin-1 in Breast Cancer Cells
Salman Hyder, PhD
The Curators of the University of Missouri
Tumor Cell Biology I
$250,000
The Role Of Dietary Antioxidants And Expression Of Nm23-H1 In Breast Cancer Skeletal Metastasis
Craig Albright, PhD
Tumor Cell Biology IV
$250,000
Annexin/lipocortin I as a unique target of mechanism-based chemoprevention of breast cancer: computer biology and in vitro new gene mutation assays.
Fusao Hirata, MD, PhD
Wayne State University
RISK and Prevention, Epidemiology
$250,000
P-TEFB, A NOVEL THERAPEUTIC TARGET FOR HUMAN BREAST CANCER
Qiang Zhou, PhD
The Regents of the University of California at Berkeley
Tumor Cell Biology II
$250,000
Regulation of SXR Activation by Rexinoids - Role in Drug Resistance
Wilson Miller, MD, PhD
Lady Davis Institute for Medical Research, McGill University
Tumor Cell Biology II
$242,765
Modulation Of Erbb2 Tumor Metabolism By Akt
Steven Anderson, PhD
Health Sciences Center, University of Colorado System
Tumor Cell Biology IV
$250,000
Characterization of the Cytotoxic CD8+ T Cell Immune Response to Mammaglobin-A
Andres Jaramillo, PhD, HCLD(ABB)
Rush University Medical Center
Tumor Cell Biology III
$249,000
Improving Mammography Performance with Tomosynthesis
David Gur, ScD
University of Pittsburgh, Office of Research
Detection, Diagnosis and Prognosis
$249,789
A Phase II Study Of Tetrathiomolybdate, An Anti-Angiogenic Agent, In Women With Breast Cancer At High Risk Of Relapse
Linda Vahdat, MD
Joan & Sanfor I. Weill Medical College of Cornell University
Treatment
$250,000
Whole-body MRI for Detecting Breast Cancer Metastases
Jingfei Ma, PhD
UT M.D. Anderson Cancer Center
Detection, Diagnosis and Prognosis
$225,900
Uric Acid Crystals as a Novel Adjuvant for HER-2/neu-Based Immunotherapy in a Somatic Mammary Carcinoma Model
Xiulong Xu, PhD
Rush University Medical Center
Tumor Cell Biology III
$247,008
Inhibition of Breast Cancer Tumor Progression by Class-3 Semaphorins
Gera Neufeld, PhD
Technion Research & Development Foundation, Ltd.
Tumor Cell Biology I
$249,900
Regulation of novel cytoskeletal protein complexes involved in breast cancer initiation and progression
Anton Wellstein, MD, PhD
Georgetown University, Lombardi Comprehensive Cancer Center
Tumor Cell Biology I
$250,000
Role of IFIX in breast cancer metastasis
Mien-Chie Hung, PhD
The University of Texas M.D. Anderson Cancer Center
Tumor Cell Biology I
$250,000
Dietary Glutamine And Protection Against Doxorubicin And Cyclophosphamide Toxicity
Valentina Todorova, PhD
The Board of Trustees of the University of Arkansas Acting for and on behalf of the University of Arkansas for Medical Services
Treatment
$249,356
Evaluating Akt Tyrosine Phosphorylation as a Novel Marker for Therapeutic Resistance and Breast Cancer Prognosis
Thomas Franke, MD, PhD
Columbia University Medical Center
Tumor Cell Biology V
$250,000
Multiplexed Biomarkers for Early Detection and Remission Monitoring of Breast Cancer
Anna Lokshin, PhD
University of Pittsburgh
Detection, Diagnosis and Prognosis
$249,837
Deuterium Labeling in DCIS: A Novel In Vivo Measure of Cell Proliferation
E. Shelley Hwang, MD
University of California, San Francisco
Detection, Diagnosis and Prognosis
$248,490
Role of Protein Kinase C delta in Mammary Gland Apoptosis and Tumorigenesis
Mary Reyland, PhD
University of Colorado at Denver and Health Sciences Center
Tumor Cell Biology V
$250,000
Human Papillomavirus Infection As A Potential Cause of Breast Cancer
Michelle Ozbun, PhD
The Regents of the University of New Mexico
Tumor Cell Biology V
$250,000
Distinct function and role of androgen receptor cofactor ARA70alpha and ARA70beta isoforms in breast cancer growth and metastasis
Peng Lee, MD, PhD
New York University School of Medicine
Tumor Cell Biology II
$250,000
ER-alpha36 and development of ER-negative breast cancer
Zhaoyi Wang, PhD
Creighton University
Tumor Cell Biology I
$250,000
The Functions of Brca1 and Brca2 in Protecting Stalled DNA Replication Forks
Lee Zou, PhD
The General Hospital Corporation
Tumor Cell Biology V
$250,000
Elucidating the Cause for the Insrease in Telomerase in Human Breast Cancer
Trygve Tollefsbol, PhD, DO
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
Tumor Cell Biology V
$250,000
The 3D telomeric signature(s) of DCIS
Sabine Mai, PhD
The University of Manitoba
Detection, Diagnosis and Prognosis
$249,805
Regulation of Breast Cancer by Progesterone Metabolites
John Wiebe, PhD
University of Western Ontario
Tumor Cell Biology IV
$250,000
Mammary Cancer Stem Cells
Anne Peaston, PhD
The Jackson Laboratory
Tumor Cell Biology V
$250,000
Ductal Carcinoma In Situ and BRCA1/2: Outcomes and Risk Prediction
Elizabeth Claus, PhD, MD
Yale University
RISK and Prevention, Epidemiology
$249,823
Use of BOEC for Cancer Gene Therapy
Arkadiusz Dudek, MD, PhD
Regents of the University of Minnesota
Treatment
$250,000
Real-Time Imaging of Human Breast Tissue by Reflectance Confocal Microscopy
Minetta Liu, MD
Georgetown University
Detection, Diagnosis and Prognosis
$250,000
In Vitro and In Vivo Models for Chemoresistance
Nira Ben-Jonathan, Ph.D
University of Cincinnati
Tumor Cell Biology IV
$250,000
Predicting Outcome in Node-Negative Breast Cancer by Integrated Genomics and Proteomics
Yuval Kluger, PhD
New York University School of Medicine
Detection, Diagnosis and Prognosis
$250,000
Restoring ER Expression and Anti-Estrogen Response to ER-Negative Breast Cancers
Dorraya El-Ashry, PhD
The Regents of the University of Michigan
Tumor Cell Biology II
$250,000
Targeting Fatty Acid Synthase (FAS)-Dependent Endogenous Fatty Acid Metabolism To Prevent Breast Cancer: FAS As A Metabolic Oncogene In Situ Ductal Carcinoma Of The Breast
Javier Menendez, PhD
Fundacio Privada D'Investigacio Biomedica de Giorna
Tumor Cell Biology V
$249,991
BC200 RNA: a novel molecular marker for DCIS and invasive breast cancer
Henri Tiedge, PhD
The Research Foundation of SUNY on behalf of Health Science Center at Brooklyn, SUNY
Detection, Diagnosis and Prognosis
$250,000
Human prolactin as a chemopreventive agent for breast cancer
Wen Chen, PhD
Greenville Hopital System
RISK and Prevention, Epidemiology
$250,000
Skeletal Metastasis and the Unique Role of Breast Cancer Stem Cells
Peter Hauschka, PhD
Children's Hospital Boston
Tumor Cell Biology I
$250,000
Combination Therapy Based on Novel Vitamin D Actions to Inhibit Breast Cancer Cell Growth
David Feldman, MD
Stanford University
Treatment
$250,000
Molecular synergy and novel targets of anti-breast cancer phytochemicals
Joseph Wu, PhD
New York Medical College
RISK and Prevention, Epidemiology
$250,000
Regulation of ER transcriptional potential by the chromatin architectural factor HMGB1
Wei Xu, PhD
Board of Regents of the University of Wisconsin System
Tumor Cell Biology II
$249,695
Role of Mitotic Checkpoint in the Sensitivity of Breast Cancer to Paclitaxel
Naoto Ueno, MD,PhD
The University of Texas M.D. Anderson Cancer Center
Tumor Cell Biology IV
$250,000
Breastfeeding History And Undifferentiated Breast Cancer
William Fraser Symmans, MD
The University of Texas, M.D. Anderson Cancer Center
RISK and Prevention, Epidemiology
$249,209
A Novel Three-Dimensional Model of Basal-like Breast Cancer
Vincent Cryns, MD
Northwestern University
Tumor Cell Biology V
$250,000
Isolation of metastasis-inhibiting monoclonal antibodies
Steve Goodison, PhD
University of Florida
Detection, Diagnosis and Prognosis
$249,559
Do Mast Cells Prevent Carcinogenesis?
Ana Soto, MD
Tufts University
Tumor Cell Biology III
$250,000
Use of a Panel of Mitotic Kinase Antibodies to Predict Pre-malignancy Outcomes in Human Breast Cancer
Sara Li, PhD
University of Kansas Medical Center
Detection, Diagnosis and Prognosis
$249,208
Design of Targeted Bacteria to Overcome Multidrug Resistance
Neil Forbes, PhD
The University of Massachusetts, Office of Grant and Contract Admin.
Treatment
$249,830
Discovery and Functional Analysis of Fusion Transcripts In Breast Cancer
Colin Collins, PhD
University of California, San Francisco
Tumor Cell Biology V
$250,000
Minor Recombination Pathways, Cellular Survival, And Tumorigenesis In The Absence Of BRCA2
Maria Jasin, PhD
Memorial Sloan-Kettering Cancer Center
Tumor Cell Biology V
$250,000
The Role of the Rho Exchange Factor NET1 in Breast Cancer
Jeffrey Frost, PhD
The University of Texas Health Science Center at Houston
Tumor Cell Biology V
$250,000
Mapping The Mammary Epithelial Cell Transformation In BRCA1 Carriers
Gerburg Wulf, MD PhD
Beth Israel Deaconess Medical Center
Tumor Cell Biology V
$249,945
Identification Of Low Molecular Weight Serum Proteins/Peptides For The Diagnosis Of Breast Cancer Disease
Tapan Maity, PhD
Windber Research Institute
Detection, Diagnosis and Prognosis
$247,870
A New In Vitro Model of Breast Cancer Metastasis to Bone
Andrea Mastro, PhD
The Pennsylvania State University
Tumor Cell Biology I
$250,000
Determinants of Weight Gain in Women with Early Stage Breast Cancer
Chi-Chen Hong, PhD
Roswell Park Alliance Foundation
RISK and Prevention, Epidemiology
$250,000
The role of G12 proteins in breast cancer invasion and metastasis
Timothy Fields, MD, PhD
Duke University
Tumor Cell Biology I
$250,000
Three-Dimensional Analysis of Shoulder Motion Limitation Following Treatment for Breast Cancer
John Borstad, PhD
The Ohio State University Research Foundation
Treatment
$168,739
Mechanisms of Cognitive Dysfunction in Breast Cancer Survivors
Ian Tannock, MD, PhD
University Health Network
Psycho-Social and Complementary Treatment
$249,680
Evaluating the Role of GKLF/KLF4 in Mammary Gland Development and Carcinogenesis
Ruth Keri, PhD
Case Western Reserve University
Tumor Cell Biology V
$250,000
Inhibition Of Constitutive Stat3 Pathway In Breast Cancer Cells By A Novel Low-Molecular-Weight Compound
Jiayuh Lin, PhD
Children's Research Institute
Treatment
$250,000
Role of GluR6 in cell senescence and in the development of breast cancer
Raghbir Athwal, PhD
Temple University
Tumor Cell Biology I
$250,000
CXCR:4 Wnt Axis in Chemoresistance of Breast Cancer Stem Cells
Harikrishna Nakshatri, BVSc, PhD
Indiana University
Tumor Cell Biology I
$250,000
Androgen receptor status as a determinant of breast cancer risk and disease progression.
Wayne Tilley, PhD
The University of Adelaide
Tumor Cell Biology II
$247,500
A Novel Target for Preventing Both Immune Tolerance and Tumor Angiogenesis to Improve Immune Enhancing Therapy for Advanced Breast Cancer
Ping-Ying Pan, PhD
Mount Sinai School of Medicine of NYU
Tumor Cell Biology III
$249,999
Mechanisms of aberrant growth signaling in a rat model of early-onset breast cancer
Susan Ozanne, BSc (Hons), Ph.D.
University of Cambridge
RISK and Prevention, Epidemiology
$248,745
Understanding Adjuvant Therapy and Clinical Trials: An Evaluation of an Online Synthetic Interview for Breast Cancer Patients
Valerie Monaco, PhD, MHCI
University of Pittsburgh
Psycho-Social and Complementary Treatment
$250,000
Identification of biomarker for activator form of estrogen-related receptor alpha in breast cancer
Janet Mertz, PhD
Board of Regents of the University of Wisconsin System
Tumor Cell Biology II
$249,582
The SDF1-CXCR4 Axis In Breast Cancer Progression And Endocrine Resistance
Matthew Burow, PhD
Tulane University Health Sciences Center
Tumor Cell Biology II
$250,000
Targeting the Neovasculature for Immunotherapy and Photodynamic Therapy of Breast Cancer
Zhiwei Hu, MD, PhD
Yale University
Treatment
$250,000
Identifying New Biomarkers for Breast Cancer using Antibody Microarray Staining
Wayne Zhou, PhD
Baton Rouge, LSU
Detection, Diagnosis and Prognosis
$250,000
Shear Strain Imaging for Breast Cancer Diagnosis
Tomy Varghese, PhD
The Board of Regents of the University of Wisconsin System
Detection, Diagnosis and Prognosis
$249,990
Validation of SHIP2 as a Novel Molecular Target in Obesity-Linked Cancer’
Nagendra Prasad, DVM, PhD
Purdue University
Tumor Cell Biology II
$250,000
Serum Glycan Analysis in Breast Cancer
Helen Chew, MD
The regents of the University of California
Detection, Diagnosis and Prognosis
$250,000
A pilot study of synthetic thyrotropin-releasing hormone (TRH) administration for the treatment of radiation therapy induced fatigue in breast cancer patients
Andrew Winokur, MD PhD
University of Connecticut Health Center
Psycho-Social and Complementary Treatment
$44,250
Methylated CpG islands as biomarkers for familial breast cancer
Georgia Chenevix-Trench, PhD
Queensland Institute of Medical Research
Detection, Diagnosis and Prognosis
$249,928
Role of CRIF1 in NRF2 signaling pathway
Insoo Bae, PhD
Georgetown University
RISK and Prevention, Epidemiology
$250,000
Immunologic Gene Expression in Sentinel Lymph Nodes
Steve Shivers, PhD
Lakeland Regional Cancer Center
Detection, Diagnosis and Prognosis
$250,000
Time-Dependent Patterns of Tumor Recurrence and Other Events After Early Stage Breast Cancer
James Dignam, PhD
University of Chicago
Detection, Diagnosis and Prognosis
$249,078
Role of MT1-MMP in protection of breast tumor cells against host immune attack
Alex Strongin, PhD
Burnham Institute for Medical Research
Tumor Cell Biology I
$250,000
Development of 3D Microfluidic Gradient Model for Metastasis
Noo Li Jeon, PhD
The Regents of the University of California
Tumor Cell Biology I
$249,927
Rational Design of Combinational Targeted Therapeutics in Breast Cancer: Towards Improving Patient Outcomes
Yiling Lu, MD
The University of Texas M.D. Anderson Cancer Center
Treatment
$250,000
Breast Positioning And Topology Monitoring System Development For Image-Guided Radiation Therapy
Jason Sohn, PhD
Case Western Reserve University
Treatment
$250,000
Glycoproteomic Identification of Prognostic Serum Biomarkers
Richard Drake, PhD
Eastern Virginia Medical School
Detection, Diagnosis and Prognosis
$250,000
Defining The Clinical And Functional Role Of An Extracellular Matrix Gene Cluster In Therapy Failure
Petronella Berns, PhD
Erasmus University Medical Center Rotterdam
Treatment
$250,000
Feasibility study of a high-resolution breast coil for PET-CT scanners
Yuan-Chuan Tai, PhD
Washington University
Detection, Diagnosis and Prognosis
$249,349
Prognostic Significance of Soluble EGFR Expression in Breast Cancer
Jill Reiter, PhD
Yale University
Detection, Diagnosis and Prognosis
$250,000
Identifying Therapeutic Targets by Expression Profiling of DNA Repair in Breast Cancer
Alexander Dobrovic, PhD
The University of Melbourne
Detection, Diagnosis and Prognosis
$249,200
Identifying New Tumor Suppressor Genes Involved In Human Breast Cancer
Mieke Schutte, PhD
Erasmus MC
Tumor Cell Biology V
$248,800
Tracking Response to Tamoxifen Prevention
Victoria L. Seewaldt, MD
Duke University School of Medicine
Treatment
$250,000
Understanding and Improving the Effectiveness of Trastuzumab-Based Therapy for Breast Cancer
Randall King, MD, PhD
President and Fellows of Harvard College on behalf of Harvard Medical School
Tumor Cell Biology IV
$250,000
translational control of metastases
Arrigo De Benedetti, PhD
LSU Health Science Center - Shreveport
Tumor Cell Biology I
$247,020
Role Of TBX3 In Breast Cancer
Taosheng Huang, MD, PhD
The Regents of the University of California
Tumor Cell Biology V
$247,225
Volumetric Estimation of Breast Percent Density from Tomosynthesis Images
Predrag Bakic, PhD
Detection, Diagnosis and Prognosis
$250,000
Comparison of the IGF and Breast Density Association by Race
Celia Byrne, PhD
Georgetown University
RISK and Prevention, Epidemiology
$250,000
Targeting JNK to Block Breast Cancer Proliferation and Metastasis
Xiaojiang Cui, PhD
Baylor College of Medicine
Tumor Cell Biology I
$249,947
MMP1-Protease Activated Receptor-1 Signaling in the Tumor-Stromal Microenvironment
Athan Kuliopulos, MD, PhD
New England Medical Center Hospitals, Inc.
Tumor Cell Biology I
$250,000
Single Molecule Studies of Homologous Recombination in Human Cells
Piero Bianco, PhD
The Research Foundation of SUNY on behalf of University at Buffalo
Tumor Cell Biology V
$249,583
Control of mammary epithelial hyperplasia and malignant progression by p21-activated kinase 1 (PAK1)
Ray Mattingly, PhD
Wayne State University
Tumor Cell Biology II
$250,000
"Genetic Modifiers of BRCA Penetrance"
Kenneth Offit, MD, MPH
Memorial Sloan-Kettering Cancer Center
RISK and Prevention, Epidemiology
$249,919
Multiple Flavonoids in the Treatment of Multidrug Resistance
Marilyn Morris, PhD
Buffalo, State University of New York System
Treatment
$250,000
* Pending executed agreement
